Clinical trial
Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated…
NCT04025632 · Ra Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT04025632 |
|---|---|
| Title | Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy |
| Official title | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy |
| Lead sponsor | Ra Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Immune Mediated Necrotizing Myopathy |
| Intervention type | Drug, Other |
| Interventions | zilucoplan, Placebo |
| Enrollment | 27 |
| Start date | Nov 7, 2019 |
| Primary completion | Mar 4, 2021 |
| Completion | Jun 14, 2021 |
| First posted | Jul 19, 2019 |
| Last update posted | Jul 27, 2022 |
| Countries | France, Netherlands, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: